Volume Spike Investor

Novavax, Inc. (NASDAQ: NVAX) is soaring on positive flu data.  As of 8:34 AM EST we have seen almost 2 million shares trade hands versus average volume of 7 million shares.  The price is surging as well by 14% to $6.91.  Chalk this up as a 52-week high as the old high was $6.30 before this morning.  Novavax’s Phase II human clinical trial of its trivalent seasonal influenza virus-like particle vaccine candidate showed positive results as the vaccine was well tolerated and induced robust immune responses against all three influenza strains in the vaccine. The company believes that the data supports the planned study in elderly adults scheduled for the fourth quarter this year and pave the way for Novavax to advance its seasonal influenza VLP vaccine into Phase III studies next year. -JON OGG